TY - JOUR
T1 - Associating SARS-CoV-2 Serological Assays with Protection
T2 - Where the Field Stands
AU - Tang, Mei San
AU - Farnsworth, Christopher W.
PY - 2021/4/29
Y1 - 2021/4/29
KW - 55 serological assays have received EUA. Nonetheless
KW - COVID-19
KW - SARS-CoV-2
KW - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 was met with a rapid introduction of commercially available serological assays for SARS-CoV-2 antibody detection. Soon after being declared an emergency in the US
KW - as laboratories gained access to this unprecedented number of assays
KW - exceeding the number of assays available for any other infectious disease and most other laboratory analytes. As a result of this rapid expansion and at times dubious quality
KW - hundreds of serological assays for SARS-CoV-2 were introduced
KW - serology
KW - the Food and Drug Administration (FDA) began reviewing and regulating all SARS-CoV-2 serological assays under emergency use authorization (EUA). To date
KW - the utility of SARS-CoV-2 serological testing remained unclear
UR - http://www.scopus.com/inward/record.url?scp=85105895044&partnerID=8YFLogxK
U2 - 10.1093/clinchem/hvab039
DO - 10.1093/clinchem/hvab039
M3 - Editorial
C2 - 33772260
AN - SCOPUS:85105895044
VL - 67
SP - 707
EP - 709
JO - Clinical Chemistry
JF - Clinical Chemistry
SN - 0009-9147
IS - 5
ER -